Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: Implications for novel therapeutic strategies

Journal of Hypertension

Volumn 31, Issue 6, 2013, Pages 1061-1072

  Rubattu, Speranza ^a,b   Calvieri, Camilla ^a   Pagliaro, Beniamino ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

ANP analogues; atrial natriuretic peptide; gene therapy; nitric oxide; NPR A; NPR C; vascular function; vasopeptidase inhibitors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; GUANYLATE CYCLASE; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; ORCIPRENALINE;

CARDIOVASCULAR FUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASODILATATION;

EID: 84877585683     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835ed5eb     Document Type: Review

References (108)

1. Bolli P, Müller FB, Linder L, Raine AE, Resink TJ, Erne P, et al. The vasodilator potency of atrial natriuretic peptide in man. Circulation 1987; 75:221-228.
2. Melo LG, Veress AT, Ackermann U, Sonnenberg H. Chronic regulation of arterial blood pressure by ANP: role of endogenous vasoactive endothelial factors. Am J Physiol 1998; 275:H1826-H1833.
3. Garcia R, Thibault G, Cantin M, Genest J. Effect of a purified atrial natriuretic factor on rat and rabbit vascular strips and vascular beds. Am J Physiol 1984; 247:R34-R39.
4. Napier MA, Vandlen RL, Albers-Schönberg G, Nutt RF, Brady S, Lyle T, et al. Specific membrane receptors for atrial natriuretic factor in renal and vascular tissues. Proc Natl Acad Sci USA 1984; 81:5946-5950.
5. Ishikawa N, Hayakawa A, Uematsu T, Nakashima M. Heterogeneity in vasorelaxant effects of alpha-human atrial natriuretic polypeptide in the dog. Jpn J Pharmacol 1987; 44:515-518.
6. Laxson DD, Dai XZ, Schwartz JS, Bache RJ. Effects of atrial natriuretic peptide on coronary vascular resistance in the intact awake dog. J Am Coll Cardiol 1988; 11:624-629.
7. Foreman B, Dai XZ, Homans DC, Laxson DD, Bache RJ. Effect of atrial natriuretic peptide on coronary collateral blood flow. Circ Res 1989; 65:1671-1678.
8. Chu A, Murray JJ, Lin CC, Russell M, Hagen PO, Cobb FR. Preferential proximal coronary dilation by activators of guanylate cyclase in awake dogs. Am J Physiol 1990; 259:H340-345.
9. Anand-Srivastava MB, Trachte GJ. Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev 1993; 45:455-497.
10. Osol G, Halpern W, Tesfamariam B, Nakayama K, Weinberg D. Synthetic atrial natriuretic factor does not dilate resistance-sized arteries. Hypertension 1986; 8:606-610.
11. Melo LG, Veress AT, Ackermann U, Steinhelper ME, Pang SC, Tse Y, Sonnenberg H. Chronic regulation of arterial blood pressure in ANP transgenic and knockout mice, role of cardiovascular sympathetic tone. Cardiovasc Res 1999; 43:437-444.
12. Schultz HD, Steele MK, Gardner DG. Central administration of atrial peptide decreases sympathetic outflow in rats. Am J Physiol 1990; 258:R1250-R1256.
13. Nakamaru M, Inagami T. Atrial natriuretic factor inhibits norepinephrine release evoked by sympathetic nerve stimulation in isolated perfused rat mesenteric arteries. Eur J Pharmacol 1986; 123:459-461.
14. Volpe M, Lembo G, Condorelli G, De Luca N, Lamenza F, Indolfi C, Trimarco B. Converting-enzyme inhibition prevents the effects of atrial-natriuretic factor on baroreflex responses in humans. Circulation 1990; 82:1214-1221.
15. Volpe M, Cuocolo A, Vecchione F, Mele AF, Condorelli M, Trimarco B. Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflex in the rabbit. Circ Res 1987; 60:747-755.
16. Lappe RW, Smits JF, Todt JA, Debets JJ, Wendt RL. Failure of atriopeptin II to cause arterial vasodilation in the conscious rat. Circ Res 1985; 56:606-612.
17. Oshima T, Currie MG, Geller DM, Needleman P. An atrial peptide is a potent renal vasodilator substance. Circ Res 1984; 54:612-616.
18. Veldkamp PJ, Carmines PK, Inscho EW, Navar LG. Direct evaluation of the microvascular actions of ANP in juxtamedullary nephrons. Am J Physiol 1988; 254:F440-444.
19. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes preglomerular vasodilatation and postglomerular vasoconstriction in rat kidney. Nature 1986; 324:473-476.
20. Edwards RM, Weidley EF. Lack of effect of atriopeptin II on rabbit glomerular arterioles in vitro. Am J Physiol 1987; 252:F317-F321.
21. Nakao N, Itakura T, Uematsu Y, Yokote H, Nakai K, Komai N. A possible involvement of central atrial natriuretic peptide in cerebral cortical microcirculation. Neurosurgery 1992; 30:236-240.
22. Klinger JR, Warburton R, Carino GP, Murray J, Murphy C, Napier M, Harrington EO. Natriuretic peptides differentially attenuate thrombininduced barrier dysfunction in pulmonary microvascular endothelial cells. Exp Cell Res 2006; 312:401-410.
23. Chen W, Gassner B, Börner S, Nikolaev VO, Schlegel N, Waschke J, et al. Atrial natriuretic peptide enhances microvascular albumin permeability by the caveolae-mediated transcellular pathway. Cardiovasc Res 2012; 93:141-151.
24. Moritoki H, Yoshikawa T, Hisayama T, Takeuchi S. Possible mechanisms of age-associated reduction of vascular relaxation caused by atrial natriuretic peptide. Eur J Pharmacol 1992; 210:61-68.
25. Hughes AD, Nielsen H, Sever PS. The effect of atrial natriuretic peptide on human isolated resistance arteries. Br J Pharmacol 1989; 97:1027-1030.
26. Winquist RJ, Faison EP, Waldman SA, Schwartz K, Murad F, Rapoport RM. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA 1984; 81:7661-7664.
27. Van der Zander K, Houben AJ, Kroon AA, de Leeuw PW. Effects of brain natriuretic peptide on forearm vasculature, comparison with atrial natriuretic peptide. Cardiovasc Res 1999; 44:595-600.
28. Minami H, Yasu T, Tagawa T, Yamakawa K, Ueda S. Slower onset of vasodilating action of brain natriuretic peptide (BNP). compared to atrial natriuretic peptide (ANP) in human forearm resistant vessels. Eur J Clin Pharmacol 2008; 64:859-862.
29. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86:1081-1088.
30. Kathiresan S, Gona P, Larson MG, Vita JA, Mitchell GF, Tofler GH, et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 2006; 113:938-945.
31. Houben AJ, Krekels MM, Schaper NC, Fuss-Lejeune MJ, Rodriguez SA, de Leeuw PW. Microvascular effects of atrial natriuretic peptide (ANP) in man: studies during high and low salt diet. Cardiovasc Res 1998; 39:442-450.
32. Schiffrin EL, Parent A, St Louis J, Tremblay J, Garcia R, Thibault G. Vascular atrial natriuretic factor receptors in spontaneously hypertensive rats. Cardiovasc Res 1992; 26:857-864.
33. Tremblay J, Huot C, Willenbrock RC, Bayard F, Gossard F, Fujio N, et al. Increased cyclic guanosine monophosphate production and overexpression of atrial natriuretic peptide A-receptor mRNA in spontaneously hypertensive rats. J Clin Invest 1993; 92:2499-2508.
34. Wei CM, Kim CH, Khraibi AA, Miller VM, Burnett JC Jr. Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro. Hypertension 1994; 23:903-907.
35. Nishimura Y, Suzuki A. Relaxant effects of vasodilator peptides on isolated basilar arteries from stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1997; 24:157-161.
36. Rubattu S, Volpe M, Kreutz R, Ganten U, Ganten D, Lindpaintner K. Chromosomal mapping of quantitative trait loci for stroke in an animal model of complex human disease. Nature Genet 1996; 13:427-432.
37. Russo R, Vecchione C, Cosentino F, Natale A, Mele AF, Muscolo M, et al. Impaired vasorelaxant responses to natriuretic peptides in the stroke-prone phenotype of spontaneously hypertensive rats. J Hypertens 1998; 16:151-156.
38. Peral de Bruno M, Romano L, Proto M, Coviello A. Atrial natriuretic peptide relaxes arterial basal tone induced by coarctation hypertension. Peptides 1999; 20:485-491.
39. Mourlon-Le Grand MC, Poitevin P, Benessiano J, Duriez M, Michel JB, Levy BI. Effect of a nonhypotensive long-term infusion of ANP on the mechanical and structural properties of the arterial wall in Wistar-Kyoto and spontaneously hypertensive rats. Arterioscler Thromb 1993; 13:640-650.
40. Larifla L, Deacute;prez I, Pham I, Rideau D, Louzier V, Adam M, et al. Inhibition of vascular smooth muscle cell proliferation and migration in vitro and neointimal hyperplasia in vivo by adenoviral-mediated atrial natriuretic peptide delivery. J Gene Med 2012; 14:459-467.
41. Kallaras K, Babas G, Stergiou-Michailidou V, Karamouzis M, Zaraboukas T. Atrial natriuretic peptide decreases aorta stiffness in cholesterol-fed anesthetized rabbits. Pharmacol Res 2009; 60:324-331.
42. Bolli P, Müller FB, Linder L, Raine AE, Resink TJ, Erne P, et al. Greater vasodilator responsiveness to atrial natriuretic peptide in low-renin essential hypertensives. J Hypertens 1987; Suppl 5:S55-S58.
43. Volpe M, De Luca N, Atlas SA, Camargo MJ, Indolfi C, Lembo G, et al. Reduction of atrial natriuretic factor circulating levels by endogenous sympathetic activation in hypertensive patients. Circulation 1988; 77:997-1002.
44. Bulut D, Potthast R, Hanefeld C, Schulz T, Kuhn M, Mügge A. Impaired vasodilator responses to atrial natriuretic peptide in essential hypertension. Eur J Clin Invest 2003; 33:567-573.
45. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986; 231:1145-1147.
46. Hirooka Y, Takeshita A, Imaizumi T, Suzuki S, Yoshida M, Ando S, Nakamura M. Attenuated forearm vasodilative response to intraarterial atrial natriuretic peptide in patients with heart failure. Circulation 1990; 82:147-153.
47. Riegger GA, Elsner D, Kromer EP, Daffner C, Forssmann WG, Muders F, et al. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects. Circulation 1988; 77:398-406.
48. Nakamura M, Arakawa N, Yoshida H, Makita S, Niinuma H, Hiramori K. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J 1998; 135:414-420.
49. Nakamura M, Arakawa N, Yoshida H, Makita S, Hiramori K. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation 1994; 90:1210-1214.
50. Kubo SH, Atlas SA, Laragh JH, Cody RJ. Maintenance of forearm vasodilator action of atrial natriuretic factor in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1306-1309.
51. Schmitt M, Gunaruwan P, Payne N, Taylor J, Lee L, Broadley AJ, et al. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol 2004; 24:911-917.
52. Serizawa T, Hirata Y, Kohmoto O, Iizuka M, Matsuoka H, Sato H, et al. Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure. Jpn Heart J 1988; 29:143-149.
53. Chinkers M, Garbers DL, Chang MS, Lowe DG, Chin HM, Goeddel DV, Schulz S. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989; 338:78-83.
54. Chang MS, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel DV. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature 1989; 341:68-72.
55. Anand-Srivastava MB, Srivastava AK, Cantin M. Pertussis toxin attenuates atrial natriuretic factor-mediated inhibition of adenylate cyclase. Involvement of inhibitory guanine nucleotide regulatory protein. J Biol Chem 1987; 262:4931-4934.
56. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005; 26:1044-1059.
57. Hamet P, Tremblay J, Pang SC, Garcia R, Thibault G, Gutkowska J, et al. Effect of native and synthetic atrial natriuretic factor on cyclic GMP. Biochem Biophys Res Commun 1984; 123:515-527.
58. Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984; 259:14332-14334.
59. Winquist RJ, Faison EP, Waldman SA, Schwartz K, Murad F. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA 1984; 1984:7661-7664.
60. Tremblay J, Gerzer R, Vinay P, Pang SC, Beacute;liveau R, Hamet P. The increase of cGMP by atrial natriuretic factor correlates with the distribution of particulate guanylate cyclase. FEBS Lett 1985; 181:17-22.
61. Lincoln TM. Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther 1989; 41:479-502.
62. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986; 78:1-5.
63. Yoshimoto T, Naruse M, Tanabe A, Naruse K, Takagi K, Muraki T, et al. Angiotensin converting enzyme inhibitor but not calcium blocker down-regulates gene expression of vascular natriuretic peptide receptor in hypertensive rats. Biochem Biophys Res Commun 1994; 205:1595-1600.
64. Nuglozeh E, Mbikay M, Stewart DJ, Legault L. Gene expression of natriuretic peptide receptors in rats with DOCA-salt hypertension. Am J Physiol 1997; 273:C1427-C1434.
65. Seguchi H, Nishimura J, Toyofuku K, Kobayashi S, Kumazawa J, Kanaide H. The mechanism of relaxation induced by atrial natriuretic peptide in the porcine renal artery. Br J Pharmacol 1996; 118:343-351.
66. Kurihara M, Gutkind JS, Saavedra JM. Alteration of atrial natriuretic peptide binding sites in spontaneously hypertensive rats. Am J Hypertens 1988; 1:12S-14S.
67. Khalil F, Fine B, Kuriyama S, Hatori N, Nakamura A, Nakamura M, Aviv A. Increased atrial natriuretic factor receptor density in cultured vascular smooth muscle cells of the spontaneously hypertensive rat. Clin Exp Hypertens A 1987; 9:741-752.
68. Bianchi C, Thibault G, Wrobel-Konrad E, De Leacute;an A, Genest J, Cantin M. Atrial natriuretic factor binding sites in experimental congestive heart failure. Am J Physiol 1989; 257:F515-F523.
69. Drexler H, Finkh M, Höing S, Toth M, Just H, Lang RE. Systemic and regional vascular effects of atrial natriuretic peptide in a rat model of chronic heart failure. Basic Res Cardiol 1987; 82:517-529.
70. Yechieli H, Kahana L, Haramati A, Hoffman A, Winaver J. Regulation of renal glomerular and papillary ANP receptors in rats with experimental heart failure. Am J Physiol 1993; 265:F119-F125.
71. Tsunoda K, Mendelsohn FA, Sexton PM, Chai SY, Hodsman GP, Johnston CI. Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ Res 1988; 62:155-161.
72. Mouawad R, Li Y, Anand-Srivastava MB. Atrial natriuretic peptide-C receptor-induced attenuation of adenylyl cyclase signaling activates phosphatidylinositol turnover in A10 vascular smooth muscle cells. Mol Pharmacol 2004; 65:917-924.
73. Brunner F, Wölkart G. Endothelial NO/cGMP system contributes to natriuretic peptide-mediated coronary and peripheral vasodilation. Microvasc Res 2001; 61:102-110.
74. Sugamori T, Ishibashi Y, Shimada T, Sakane T, Takahashi N, Ohata S, et al. Nitric oxide-mediated vasodilatory effect of atrial natriuretic peptide in forearm vessels of healthy humans. Clin Exp Pharmacol Physiol 2002; 29:92-97.
75. Hussain MB, MacAllister RJ, Hobbs AJ. Reciprocal regulation of cGMPmediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol 2001; 280:H1151-H1159.
76. Elesgaray R, Caniffi C, Ierace DR, Jaime MF, Fellet A, Arranz C, Costa MA. Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide. Regul Pept 2008; 151:130-134.
77. Rubattu S, Giliberti R, Russo R, Gigante B, Ganten U, Volpe M. Analysis of the genetic basis of the endothelium-dependent impaired vasorelaxation in the stroke-prone spontaneously hypertensive rat, a candidate gene approach. J Hypertens 2000; 18:161-165.
78. Gigante B, Rubattu S, Stanzione R, Lombardi A, Schiavoni M, Tarasi D, Volpe M. Genetic factors underlying impaired endothelium-dependent vasorelaxation in the stroke-prone spontaneously hypertensive rat, a random marker genome screening approach. High Blood Press Cardiov Prev 2003; 10:69-73.
79. Iemitsu M, Maeda S, Otsuki T, Sugawara J, Kuno S, Ajisaka R, Matsuda M. Arterial stiffness, physical activity, and atrial natriuretic peptide gene polymorphism in older subjects. Hypertens Res 2008; 31:767-774.
80. Kangawa K, Tawaragi Y, Oikawa S, Mizuno A, Sakuragawa Y, Nakazato H, et al. Identification of rat gamma atrial natriuretic polypeptide and characterization of the cDNA encoding its precursor. Nature 1984; 312:152-155.
81. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J 2010; 159:949-955.
82. Hattori H, Minami Y, Mizuno M, Yumino D, Hoshi H, Arashi H et al. (2012). Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes. Heart Vessels 2012 [Epub ahead of print].
83. Nishi K, Sato Y, Miyamoto T, Toma M, Taniguchi R, Fukuhara R, et al. Intermittent infusions of carperitide or inotropes in out-patients with advanced heart failure. J Cardiol 2012; 59:366-373.
84. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J. Hypertens 1999; 17:S37-S43.
85. Murphy LJ, Corder R, Mallet AI, Turner AJ. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br J Pharmacol 1994; 113:137-142.
86. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992; 10:607-713.
87. Kentsch M, Otter W, Drummer C, Nötges A, Gerzer R, Müller-Esch G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol 1996; 51:269-272.
88. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE). trial. Am J Hypertens 2004; 17:103-111.
89. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure, IMPRESS randomised trial. Lancet 2000; 356:615-620.
90. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106:920-926.
91. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003; 41:383-389.
92. Tabrizchi R. Omapatrilat. Bristol-Myers Squibb. Curr Opin Investig Drugs 2001; 2:1414-1422.
93. Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens 2008; 26:322-333.
94. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010; 50:401-414.
95. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, doubleblind, placebo-controlled, active comparator study. Lancet 2010; 375:1255-1266.
96. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009; 32:826-834.
97. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 2011; 32:2739-2747.
98. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2012 [Epub ahead of print].
99. Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, et al. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril) inhibits systemic conversion of big endothelin-1 in humans. Life Sci 2012; 91:743-748.
100. Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, et al. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension 2011; 57:755-763.
101. Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol 2004; 43:489-494.
102. Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, et al. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens 2002; 20:707-714.
103. Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension 1995; 26:847-853.
104. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension 1999; 33:219-224.
105. Schillinger KJ, Tsai SY, Taffet GE, Reddy AK, Marian AJ, Entman ML, et al. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Natl Acad Sci USA 2005; 102:13789-13794.
106. Therrien JP, Kim SM, Terunuma A, Qin Y, Tock CL, Pfützner W, et al. A gene therapy approach for long-term normalization of blood pressure in hypertensive mice by ANP-secreting human skin grafts. Proc Natl Acad Sci USA 2010; 107:1178-1183.
107. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, et al. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension 2010; 56:1152-1159.
108. McKie PM, Ichiki T, Burnett JC Jr. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep 2012; 14:62-69.